Toyama Chemical gets Japanese rights to Cempra's solithromycin
Antibiotics developer Cempra Inc. has licensed Toyama Chemical Co. Ltd. (majority owned by Fujifilm Holdings Corp.) exclusive rights to develop and commercialize in Japan its solithromycin (CEM101)--or any product that incorporates the active pharmaceutical ingredient--for all indications except ophthalmic.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.